[go: up one dir, main page]

WO2000073801A3 - Breast, gastric and prostate cancer associated antigens and uses therefor - Google Patents

Breast, gastric and prostate cancer associated antigens and uses therefor Download PDF

Info

Publication number
WO2000073801A3
WO2000073801A3 PCT/US2000/014749 US0014749W WO0073801A3 WO 2000073801 A3 WO2000073801 A3 WO 2000073801A3 US 0014749 W US0014749 W US 0014749W WO 0073801 A3 WO0073801 A3 WO 0073801A3
Authority
WO
WIPO (PCT)
Prior art keywords
associated antigens
molecules
cancer
cancer associated
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/014749
Other languages
French (fr)
Other versions
WO2000073801A2 (en
Inventor
Yuichi Obata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Priority to JP2001500870A priority Critical patent/JP2003518364A/en
Priority to AU50478/00A priority patent/AU5047800A/en
Priority to US09/979,932 priority patent/US7166573B1/en
Priority to EP00932804A priority patent/EP1259812A2/en
Publication of WO2000073801A2 publication Critical patent/WO2000073801A2/en
Anticipated expiration legal-status Critical
Publication of WO2000073801A3 publication Critical patent/WO2000073801A3/en
Priority to US11/656,200 priority patent/US20070128655A1/en
Priority to US12/254,078 priority patent/US7879981B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G01N33/5758—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast, gastric and prostate cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.
PCT/US2000/014749 1999-05-28 2000-05-26 Breast, gastric and prostate cancer associated antigens and uses therefor Ceased WO2000073801A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001500870A JP2003518364A (en) 1999-05-28 2000-05-26 Breast, gastric and prostate cancer-related antigens and uses thereof
AU50478/00A AU5047800A (en) 1999-05-28 2000-05-26 Breast, gastric and prostate cancer associated antigens and uses therefor
US09/979,932 US7166573B1 (en) 1999-05-28 2000-05-26 Breast, gastric and prostate cancer associated antigens and uses therefor
EP00932804A EP1259812A2 (en) 1999-05-28 2000-05-26 Breast, gastric and prostate cancer associated antigens and uses therefor
US11/656,200 US20070128655A1 (en) 1999-05-28 2007-01-22 Breast, gastric and prostate cancer associated antigens and uses therefor
US12/254,078 US7879981B2 (en) 1999-05-28 2008-10-20 Breast, gastric and prostate cancer associated antigens and uses therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13652699P 1999-05-28 1999-05-28
US60/136,526 1999-05-28
US15345499P 1999-09-10 1999-09-10
US60/153,454 1999-09-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09979932 A-371-Of-International 2000-05-26
US11/656,200 Division US20070128655A1 (en) 1999-05-28 2007-01-22 Breast, gastric and prostate cancer associated antigens and uses therefor

Publications (2)

Publication Number Publication Date
WO2000073801A2 WO2000073801A2 (en) 2000-12-07
WO2000073801A3 true WO2000073801A3 (en) 2002-09-12

Family

ID=26834386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014749 Ceased WO2000073801A2 (en) 1999-05-28 2000-05-26 Breast, gastric and prostate cancer associated antigens and uses therefor

Country Status (4)

Country Link
EP (1) EP1259812A2 (en)
JP (1) JP2003518364A (en)
AU (1) AU5047800A (en)
WO (1) WO2000073801A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6737040B1 (en) 1998-08-04 2004-05-18 Diadexus, Inc. Method and antibody for imaging breast cancer
US6730477B1 (en) 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
EP1006184A1 (en) * 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6518237B1 (en) 1998-12-28 2003-02-11 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6958361B2 (en) 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6262247B1 (en) * 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
WO2001040269A2 (en) 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
WO2001047959A2 (en) * 1999-11-30 2001-07-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
EP1666495A1 (en) * 1999-12-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2001161374A (en) * 1999-12-13 2001-06-19 Akihiro Abe Polynucleotides, polypeptides, cancer therapeutics and vaccines
US6818419B2 (en) 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
AU2001236782A1 (en) * 2000-02-08 2001-08-20 Agensys, Inc. 34p3d7: a tissue specific protein highly expressed in prostate cancer
WO2001077168A2 (en) * 2000-04-11 2001-10-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2004535765A (en) 2000-12-07 2004-12-02 カイロン コーポレイション Endogenous retrovirus up-regulated in prostate cancer
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
AU2002231736A1 (en) * 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
WO2002072610A2 (en) * 2001-03-14 2002-09-19 The Regents Of The University Of California Rbp1l1, a novel retinoblastoma binding protein-related gene encoding an antigenic epitope and methods of using thereof
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
DK1434592T3 (en) * 2001-04-10 2009-03-09 Agensys Inc Nucleic acid and corresponding protein designated 121P2A3 useful for the treatment and detection of cancer
KR100405919B1 (en) 2001-06-05 2003-11-14 주식회사 이매진 Pharmaceutical composition for immunological enhancement comprising N-terminal peptide of p43 as an effective component
US7147855B2 (en) 2001-12-07 2006-12-12 Juan Saus GIPs, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein
AU2002368276A1 (en) * 2001-12-07 2004-05-13 Chiron Corporation Endogenous retrovirus up-regulated in prostate cancer
US7319138B2 (en) 2002-04-18 2008-01-15 The General Hospital Corporation Human DRG11-Responsive Axonal Guidance and Outgrowth of Neurite (DRAGON) proteins and variants thereof
JP2004057003A (en) * 2002-06-03 2004-02-26 Norihiro Chano Rb1 gene-induced protein (rb1cc1) and gene
ATE545651T1 (en) 2002-06-13 2012-03-15 Novartis Vaccines & Diagnostic VECTORS FOR EXPRESSING HML-2 POLYPEPTIDES
EP1380644A1 (en) * 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
FR2849039B1 (en) * 2002-12-24 2010-10-01 Centre Nat Rech Scient NOVEL PROTEIN ASSOCIATED WITH CENTROSOMES AND ITS APPLICATIONS
ATE451617T1 (en) * 2003-03-19 2009-12-15 Hamamatsu Found Sci & Tech Pro METHOD FOR DETECTING A COLON CANCER MARKER
JP2006523440A (en) 2003-04-15 2006-10-19 ゼノン ファーマスーティカルス，インコーポレイテッド Juvenile hemochromatosis gene (HFE2A), its expression product and method of use
EP2093569A3 (en) * 2004-05-21 2009-11-11 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
JP2008512120A (en) * 2004-09-08 2008-04-24 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Cancer-testis antigen
KR101493773B1 (en) 2006-10-17 2015-03-03 온코세라피 사이언스 가부시키가이샤 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EP2854842A4 (en) 2012-05-25 2016-11-02 Agenus Inc IDENTIFICATION OF BREAST CANCER CLASS I MHC PHOSPHOPEPTIDE ANTIGENS USING SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES
CA2883569A1 (en) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
AU2013312529A1 (en) 2012-09-05 2015-04-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
CA2894885A1 (en) * 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
US10654908B2 (en) 2014-04-15 2020-05-19 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
BR112018006894A2 (en) 2015-10-08 2018-10-16 Oncotherapy Science, Inc. mphosph1-derived peptide and vaccine that includes the same
AU2018256435B2 (en) 2017-04-20 2025-03-13 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
WO2020022902A1 (en) * 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
CN109055555B (en) * 2018-08-27 2021-09-21 中山大学 Lung cancer early stage metastasis diagnosis marker and kit and application thereof
CN114606324B (en) * 2022-05-10 2022-08-05 上海晟燃生物科技有限公司 Kit and system for assisting low-dose CT in screening lung cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 14 December 1998 (1998-12-14), "Homo sapiens HSP105 alpha mRNA", XP002177945 *
DATABASE EMBL 16 August 2000 (2000-08-16), "Human endogenous retrovirus HERV-K(II)", XP002184414 *
DATABASE EMBL 2 June 1998 (1998-06-02), "Homo sapien antigen NY-CO-25 mRNA", XP002177944 *
ISHIHARA K ET AL: "Molecular cloning, expression and localization of human 105 kDa heat shock protein, hsp105.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1444, no. 1, 18 January 1999 (1999-01-18), pages 138 - 142, XP001024442 *
SCANLAN M J ET AL: "Characterization of human colon cancer antigens recognized by autologous antibodies.", INTERNATIONAL JOURNAL OF CANCER, vol. 76, no. 5, 29 May 1998 (1998-05-29), pages 652 - 658, XP002103186 *
SUGIMOTO J ET AL: "Transcriptionally active HERV-K genes: Identification, isolation, and chromosomal mapping.", GENOMICS, vol. 72, no. 2, 1 March 2001 (2001-03-01), pages 137 - 144, XP002184413 *
TÜRECI O ET AL: "Serological analysis of human tumor antigens: molecular definition and implications", MOLECULAR MEDICINE TODAY, vol. 3, no. 8, August 1997 (1997-08-01), pages 342 - 349, XP000985587 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US7641905B2 (en) 2001-04-10 2010-01-05 Agensys, Inc. Methods of inducing an immune response
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9273302B2 (en) 2012-02-16 2016-03-01 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Also Published As

Publication number Publication date
WO2000073801A2 (en) 2000-12-07
JP2003518364A (en) 2003-06-10
EP1259812A2 (en) 2002-11-27
AU5047800A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
WO2000073801A3 (en) Breast, gastric and prostate cancer associated antigens and uses therefor
WO2001053349A3 (en) Small cell lung cancer associated antigens and uses therefor
WO2000020587A3 (en) Cancer associated antigens and uses therefor
TW428026B (en) Bifunctional protein, preparation and use
WO2002086071A3 (en) Cancer-testis antigens
CA2413857A1 (en) Pd-l2 molecules: pd-1 ligands and uses therefor
WO1999066025A3 (en) Mtbx protein and nucleic acid molecules and uses therefor
BR0009323A (en) Human antibodies that bind human il-12 and methods for production
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
ATE366814T1 (en) GL50 MOLECULES, AND USES THEREOF
AU6063500A (en) Glycoprotein vi and uses thereof
NZ331866A (en) Compounds for immunotherapy and immunodiagnosis of prostate cancer
WO2000052047A3 (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
WO2002078526A3 (en) Cancer-testis antigens
EP1009752A4 (en) Novel molecules of the tango-77 related protein family and uses thereof
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
WO1998011221A3 (en) CAR, a novel coxsackievirus and adenovirus receptor
WO2001000826A3 (en) Novel molecules of the card-related protein family and uses thereof
WO2000046236A3 (en) Novel rgs-containing molecules and uses thereof
WO2000019988A8 (en) NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
EP1208196A4 (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
WO1998011238A3 (en) Protease m, a novel serine protease
WO2001000874A3 (en) Cancer associated antigens and uses therefor
WO2000061774A3 (en) Bone morphogenic proteins
WO2001040271A3 (en) Cancer associated antigens and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 500870

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000932804

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000932804

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000932804

Country of ref document: EP